Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn.
The incidence of Rh D haemolytic disease of the fetus and newborn has been dramatically reduced by the prophylactic administration of anti-D immunoglobulin to Rh D-negative women. This preventive treatment depends on adequate supplies of anti-D derived from plasma of immunised donors, and replacement with monoclonal anti-D would be advantageous. Two monoclonal antibodies, BRAD-3 (IgG3) and BRAD-5 (IgG1) have been produced from EBV-transformed B-lymphoblastoid cell lines in Bristol and extensively characterised. Both have shown good (but differing) functional activities, determined by study of interactions of anti-D coated red cells with effector cells bearing IgG Fc receptors. Phase I clinical trials using Rh D negative male volunteers were undertaken in Bristol. The plasma half lives of BRAD-3 and BRAD-5 were characteristic for their IgG subclass, and both anti-D mediated accelerated circulatory clearance of D-positive red cells infused two days after i.m. injection of the antibodies. BRAD-3 and BRAD-5 were then shown to protect the volunteers from mounting a primary anti-D response to these D-positive red cells, and thus they may be suitable for Rh D prophylaxis of Rh D-negative women.
Kumpel
B M
BM
International Blood Group Reference Laboratory, Bristol, UK.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000918:Antibody Specificity; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007231:Infant, Newborn; D007518:Isoantibodies / Q000627:therapeutic use*; D008297:Male; D011247:Pregnancy; D017452:Receptors, IgG / Q000276:immunology; D012203:Rh Isoimmunization / Q000628:therapy*; D018029:Rho(D) Immune Globulin
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007518:Isoantibodies; C061961:RHO(D) antibody; D017452:Receptors, IgG; D018029:Rho(D) Immune Globulin